Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor in pediatric sickle cell disease
NCT03615924Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of ticagrelor in sickle cell disease (SCD), sponsored by AstraZeneca. Started Sep 2018; status: terminated.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03615924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615924.